ETFs Genmab A/S

GMAB

DK0010272202

Biotechnology & Medical Research

Real-time Estimate Cboe Europe Other stock markets 11:25:17 04/12/2024 GMT			5-day change	1st Jan Change
1,537.00 ^DKK	+0.36%		+3.29%	-28.68%

08:00am	Scancell Holdings plc Announces Genmab Exercises Option to A Second Commercial License Agreement	CI
12-03	Genmab A/S Presents at Citi's 2024 Global Healthcare Conference, Dec-03-2024 02:30 PM

ETFs positioned on Genmab A/S

Name	Weight	AuM	1st Jan change	Investor Rating
XACT NORDEN (UCITS ETF) - SEK	3.64%	203 M€	+14.21%
HAN-GINS TECH MEGATREND EQUAL WEIGHT UCITS ETF - USD	1.01%	83 M€	+19.08%
NOMURA NEXT FUNDS INTERNATIONAL EQUITY MSCI-KOKUSAI (YEN-HEDGED) ETF - JPY	0.75%	20 M€	+16.48%	-
VANECK SUSTAINABLE WORLD EQUAL WEIGHT UCITS ETF - EUR	0.56%	772 M€	+17.51%
VANECK MULTI-ASSET GROWTH ALLOCATION UCITS ETF - EUR	0.45%	27 M€	+12.59%	-
AMUNDI MSCI EUROPE EX UK UCITS ETF (C) - EUR	0.33%	6 M€	-.--%	-
ISHARES ESG MSCI EAFE LEADERS INDEX ETF - CAD	0.33%	4 M€	-.--%	-
VANECK MULTI-ASSET BALANCED ALLOCATION UCITS ETF - EUR	0.32%	36 M€	+10.29%	-
UBS (IRL) ETF PLC MSCI EUROPE ESG UNIVERSAL LOW CARBON SELECT UCITS ETF - ACC - EUR	0.31%	6 M€	-.--%
RBC QUANT EAFE EQUITY LEADERS ETF - USD	0.29%	2 M€	+9.19%	-
RBC QUANT EAFE EQUITY LEADERS (CAD HEDGED) ETF - HEDGED CAD	0.29%	2 M€	-.--%	-
JPMORGAN ACTIVEBUILDERS INTERNATIONAL EQUITY ETF - USD	0.24%	29 M€	+8.37%	-
DEMOCRACY INTERNATIONAL FUND ETF - USD	0.20%	8 M€	+5.78%	-
VANECK MULTI-ASSET CONSERVATIVE ALLOCATION UCITS ETF - EUR	0.19%	20 M€	+7.48%	-
AMUNDI INDEX MSCI WORLD SRI PAB - UCITS ETF DR - HEDGED EUR (C)	0.14%	469 M€	-1.75%
AMUNDI INDEX MSCI WORLD SRI PAB UCITS ETF - EUR	0.14%	3,859 M€	+18.82%
SIMPLIFY DEVELOPED EX-US PLUS DOWNSIDE CONVEXITY ETF - USD	0.14%	10 M€	-3.35%	-
VANGUARD INTERNATIONAL EQUITY INDEX FUNDS - VANGUARD FTSE ALL-WORLD EX-US ETF	0.11%	33,076 M€	+13.38%	-
AMUNDI MSCI WORLD ESG LEADERS SELECT - UCITS ETF DR (C) - USD	0.09%	276 M€	+11.40%	-
CSIF (IE) MSCI WORLD ESG LEADERS BLUE UCITS ETF - BH - EUR	0.08%	274 M€	+15.64%	-
CSIF (IE) MSCI WORLD ESG LEADERS BLUE UCITS ETF - BH - CHF	0.08%	216 M€	+14.54%	-
CSIF (IE) MSCI WORLD ESG LEADERS BLUE UCITS ETF - B - USD	0.08%	453 M€	-.--%
IMGP RBA RESPONSIBLE GLOBAL ALLOCATION ETF - USD	0.07%	7 M€	+0.11%	-
LEVERAGE SHARES PLC - 3X LONG TOTAL WORLD ETP	0.06%	0 M€	-.--%	-
NOMURA NEXT FUNDS INTERNATIONAL EQUITY MSCI-KOKUSAI (UNHEDGED) ETF - JPY	0.04%	329 M€	+28.52%
LYXOR MSCI WORLD CLIMATE CHANGE (DR) UCITS ETF - ACC - USD	0.04%	206 M€	-.--%
AMUNDI INDEX MSCI WORLD UCITS ETF DR (D) - EUR	0.04%	607 M€	-0.19%
AMUNDI INDEX MSCI WORLD UCITS ETF - EUR	0.04%	1,166 M€	+0.26%	-
AMUNDI MSCI WORLD CLIMATE TRANSITION CTB UCITS ETF DR (C) - USD	0.04%	23 M€	-.--%	-
AMUNDI MSCI WORLD CLIMATE TRANSITION CTB UCITS ETF DR (C) - EUR	0.04%	786 M€	-.--%
VANGUARD LIFESTRATEGY 80% EQUITY UCITS ETF ACC - EUR	0.04%	503 M€	+22.10%	-

1 2

Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows: - royalties (83.2%); - income from research and development (12.4%); - other (4.4%): primarily income from partnership agreement. At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase. Denmark accounts for all net sales.

Employees

2,635

Sector

Biotechnology & Medical Research

Calendar

06/12/2024 - American Society of Hematology Meeting - Abstract No: 7802

More about the company